© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 02, 2021
The study represents the first to examine a PPD connection to allopregnanolone.
March 31, 2021
Patients who continued taking semaglutide after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.
March 26, 2021
An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.
March 25, 2021
Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.
The therapy could offer a therapeutic option with a better safety profile, investigators said.
March 21, 2021
A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.
A majority of surveyed patients and providers want to continue telemedicine follow-up visits after the pandemic ends.
Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.
March 20, 2021
In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,
Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.